Clinician competence in treating patients of various racial and ethnic backgrounds and the critical need for greater inclusion of diverse populations in trials investigating the pathophysiology and treatment of AD are underscored.
The measurement properties of Patient-Reported Outcomes Measurement Information System Global Health in adult patients with atopic dermatitis is examined.
For moderate-to-severe atopic dermatitis, the oral Janus kinase 1 (JAK1) inhibitor abrocitinib at 200 mg or 100 mg once daily results in significantly greater reductions in signs and symptoms versus placebo.
Patients with mild to moderate atopic dermatitis and comorbid asthma or allergic rhinitis treated with crisaborole had significantly higher treatment success rates compared with vehicle control.
The benefit of a combination of dupilumab treatment with a short course of narrow-band ultraviolet B phototherapy for patients with severe atopic dermatitis was quantified.
Children with atopic dermatitis who were treated with dupilumab and topical corticosteroids showed improvements in treatment success compared with topical corticosteroids alone.
